Jade Biosciences (JBIO) Accumulated Expenses (2020 - 2026)

Jade Biosciences has reported Accumulated Expenses for 7 years, with the latest figure at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 824.21% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (up 824.21% YoY), and the FY2025 full-year result was $9.4 million, up 128.34% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $14.9 million, up from $9.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $14.9 million in Q1 2026, with the low at $1.3 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $6.4 million across 5 years, with a median of $4.7 million in 2024.
• Annual changes were most pronounced in 2025 — Accumulated Expenses tumbled 83.52% — and 2026, when it surged 824.21%.
• Jade Biosciences' Accumulated Expenses stood at $2.8 million in 2022, then surged by 438.75% to $14.8 million in 2023, then sank by 72.17% to $4.1 million in 2024, then jumped by 128.34% to $9.4 million in 2025, then soared by 57.68% to $14.9 million in 2026.
• The last three Accumulated Expenses figures came in at $14.9 million (Q1 2026), $9.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.